Kintsugi is a Berkeley, California-based mental health AI company building voice biomarker technology that detects signs of depression and anxiety from short samples of free speech. The premise is to give clinicians an objective, scalable signal for mental health, helping close gaps in detection and measurement.
The company's KiVA platform is a voice biomarker API offered to enterprises as a clinical decision-support tool, providing real-time scoring on patients' mental health. It integrates with clinical call centers, telehealth platforms, and remote patient monitoring apps so mental health signals can be surfaced during routine interactions rather than only in dedicated assessments.
Kintsugi raised a $20M Series A led by Insight Partners, with participation from Acrew Capital, Darling Ventures, Citta Capital, Side Door Ventures, Primetime Partners, IT Farm, AngelList Fund, and Alpha Edison. More recently the company released its voice biomarker models, scientific methodologies, and research to the public.
Founded in 2019, Kintsugi reflects the emerging field of vocal biomarkers for behavioral health, aiming to make objective mental health measurement available wherever patients are already speaking with care teams.